Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma—Prevalence, Clinicopathological Variables, and Clinical Outcomes

Badowska-Kozakiewicz, Anna M.; Fudalej, Marta; Kwaśniewska, Daria; Durlik, Marek; Nasierowska‐Guttmejer, Anna; Mormul, Agata; Włoszek, Emilia; Czerw, Aleksandra; Banaś, Tomasz; Deptała, Andrzej

doi:10.3390/cancers14122840

Cited by 9 publications

(8 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to long-standing DM, it is linked to lower overall survival rates [ 44 ], but blood glucose levels were significantly improved after pancreatectomy [ 45 , 46 , 47 ]. Moreover, new-onset DM acts protectively against chemotherapy, as these patients are more resistant to neutropenia [ 48 ]. To manage cancer-related DM, metformin was considered the treatment of choice, as it was found to suppress tumor development [ 49 , 50 ].…”

Section: Discussionmentioning

confidence: 99%

Synchronous Pancreatic Ductal Adenocarcinoma in the Head and Tail, a Double Trouble: A Case Report and Literature Review

Paramythiotis

Mavropoulou²,

Karlafti³

et al. 2022

Diagnostics

View full text Add to dashboard Cite

Synchronous primary pancreatic ductal adenocarcinoma (PDAC) is very rare and can be formed either through multicentric carcinogenesis or intrapancreatic metastasis. We report the case of an 80-year-old man with a history of type 2 diabetes mellitus who presented with abdominal pain and weight loss. Laboratory tests showed elevated levels of blood glucose and CA 19-9, and Computed Tomography revealed two hypoenhancing lesions in the head and tail of the pancreas. Endoscopic ultrasound, which is the imaging method of choice for pancreatic cancer, was performed with a fine needle biopsy, and the cytological analysis diagnosed PDAC in both lesions. The patient underwent total pancreatectomy, and pathologic evaluation revealed synchronous primary PDAC with moderate to poor differentiation in the head and tail in the setting of IPMN (intraductal papillary mucinous neoplasia) and chronic pancreatitis. After his recovery from postoperative pulmonary embolism, the patient was discharged home with sufficient glycemic control. Multifocal PDAC occurs more often when precursor lesions, such as IPMN, pre-exist. The optimal treatment for multiple lesions spread all over the pancreas is total pancreatectomy. Diabetes mellitus is a serious complication of total pancreatectomy (new-onset or type 3c), but overall, long-term survival has been significantly improved.

show abstract

Section: Discussionmentioning

confidence: 99%

Synchronous Pancreatic Ductal Adenocarcinoma in the Head and Tail, a Double Trouble: A Case Report and Literature Review

Paramythiotis

Mavropoulou²,

Karlafti³

et al. 2022

Diagnostics

View full text Add to dashboard Cite

show abstract

“…There is growing evidence that diabetes is a high risk factor for PC incidence, 3 , 4 , 5 , 6 and patients with diabetes have a 1.5‐ to 2‐fold increased risk of developing PC. 7 Nevertheless, the impact of diabetes on the prognosis of PC remains uncertain.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of glucose‐lipid metabolic index in pancreatic cancer patients with diabetes mellitus

Wang,

Ruan,

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThe incidence of pancreatic cancer (PC) is higher in diabetic patients due to disturbances in glucose and lipid metabolism caused by insulin resistance (IR). However, the effect of diabetes as well as IR on the prognosis of PC patients remains inconclusive. Our study aims to assess the impact of IR on the prognosis of PC patients with diabetes.MethodsWe conducted a retrospective analysis of 172 PC patients with diabetes in our institute from 2015 to 2021. Prognostic assessment was performed using univariate/multifactorial analysis and survival analysis. The predictive efficacy of metabolic indices was compared using receiver operator characteristic (ROC) curve analysis.ResultsOne hundred twenty‐one of 172 patients died during follow‐up, with a median follow‐up of 477 days and a median overall survival (OS) of 270 days. Survival analysis showed a significant difference in OS by IR related parameters, which were triglyceride‐glucose index (TyG), triglyceride‐glucose index‐body mass index (TyG‐BMI), and triglyceride/high‐density lipoprotein cholesterol ratio (TG/HDL‐c). The ROC curve indicated that TyG, TyG‐BMI, and TG/HDL‐c had prognostic efficacy for PC with diabetes. We next optimized TyG‐BMI and obtained a new parameter, namely glucose‐lipid metabolism index (GLMI), and the patients were classified into GLMI low group and high group based on the calculated cutoff value. The GLMI high group had higher TyG, TyG‐BMI, TyG/HDL‐c, BMI, TG, total cholesterol (TC), TC/HDL‐c, fasting plasma glucose, CA199, and more advanced tumor stage compared to low group. Univariate and multivariate analyses showed that GLMI was an independent prognostic factor. Furthermore, the patients of GLMI high group had worse OS compared to low group and the ROC curves showed GLMI had better predictive ability than TyG and TyG‐BMI.ConclusionsIR is associated with the outcome of PC patients with diabetes and higher level of IR indicates worse prognosis. GLMI has a good predictive value for PC with diabetes.

show abstract

“…This type of diabetes carries a heightened risk for PC, particularly compared to LSDM. Hence, NODM is considered an early marker of PC (Anna et al, 2022;Satish et al, 2015;Shreya et al, 2022). LSDM typically affects adults over 40 and is often linked to insufficient insulin production.…”

Section: Introductionmentioning

confidence: 99%

Global research trends and hotspots between pancreatic cancer and diabetes from2004 to 2024: A bibliometric analysis

Wang,

Xu,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Pancreatic cancer is one of the malignant tumors of digestive tract. In recent years, more and more studies have shown that there is a close and complex relationship between diabetes and pancreatic cancer. However, there is no bibliometric analysis of pancreatic cancer and diabetes. Methods Literature on pancreatic cancer and diabetes was retrieved and downloaded from the Web of science (WoSCC) database between January 1, 2004 and March 6, 2024. Using Microsoft Excel2021, CiteSpace, VOSviewer, Bibliometrix Package, and the bibliometric online analysis tool (ww.bibliometric.com), we analyze published literature, countries, authors, institutions, journals, co-citations, and keywords to visualize research trends and hotspots. Results A total of 2264 articles meeting both inclusion and exclusion criteria were retrieved. The trend of publications has been fluctuating. The United States (= 816,36.04%), China (= 411,18.15%) and Japan (= 203,8.97%) are the top three countries with the highest number of published articles. There is close cooperation between European and American countries. NIH is the organization that publishes the most articles. CHARI ST (n = 41) was the most prolific author. CANCER RESEARCH is the most popular journal in this field."Early prediction of Pancreatic cancer" is the main research topic at present. "molecular mechanisms", "prediction" and "chemotherapy" are top keywords in recent years. Conclusion This study shows that the early prediction of pancreatic cancer is an important topic in the study of the association between pancreatic cancer and diabetes. There are few In-depth studies of molecular mechanisms between diabetes and pancreatic cancer, which will provide new insights .

show abstract

Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma—Prevalence, Clinicopathological Variables, and Clinical Outcomes

Cited by 9 publications

References 68 publications

Synchronous Pancreatic Ductal Adenocarcinoma in the Head and Tail, a Double Trouble: A Case Report and Literature Review

Synchronous Pancreatic Ductal Adenocarcinoma in the Head and Tail, a Double Trouble: A Case Report and Literature Review

Prognostic significance of glucose‐lipid metabolic index in pancreatic cancer patients with diabetes mellitus

Global research trends and hotspots between pancreatic cancer and diabetes from2004 to 2024: A bibliometric analysis

Contact Info

Product

Resources

About